None
Quote | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Last: | $3.01 |
---|---|
Change Percent: | -0.33% |
Open: | $3.08 |
Close: | $3.01 |
High: | $3.13 |
Low: | $2.97 |
Volume: | 1,564,294 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
News | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...
Message Board Posts | Allogene Therapeutics Inc. (NASDAQ:ALLO)
Subject | By | Source | When |
---|---|---|---|
An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/1 | jondoeuk | investorshub | 03/22/2023 9:14:22 PM |
A proprietary approach to control rejection https://www.globenewswire.com/news-r | jondoeuk | investorshub | 03/22/2023 9:12:05 PM |
R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/ | jondoeuk | investorshub | 03/22/2023 9:09:42 PM |
ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allo | jondoeuk | investorshub | 05/19/2022 5:36:05 PM |
New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/68 | jondoeuk | investorshub | 03/24/2022 3:08:02 AM |
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE)...
Conference Call and Webcast Scheduled for May 13, 2024 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...